ABVC Biopharma Inc. held its 2025 annual meeting of shareholders on June 3, 2025. During the meeting, shareholders voted on several proposals. The re-election of 11 directors to the board of directors was approved. An increase in the Company's Amended and Restated 2016 Equity Incentive Plan was also approved. Furthermore, the proposal to authorize the entry into an agreement to purchase land owned by a director, Shuling Jiang, was approved. Additionally, Simon & Edward, LLP was reappointed as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.